Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-02-11

Clinical Trial Update: Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating crizotinib as neoadjuvant therapy in patients with non-small cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Crizotinib (crizotinib)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Lung Cancer, Nonsmall Cell | Phase 2 | Status: COMPLETED | Results posted: 2022-02-11